Dr. Esplin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1055 N 500 W
Ste 202
Provo, UT 84604Phone+1 801-374-2367Fax+1 801-374-2367
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2014 - 2017- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2011 - 2014
University of Oklahoma College of MedicineClass of 2011
Certifications & Licensure
UT State Medical License 2017 - 2026
MN State Medical License 2012 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 246 citationsChronic Exposure to a TLR Ligand Injures Hematopoietic Stem CellsBrandt L. Esplin, Tomoyuki Shimazu, Robert S. Welner, Karla P. Garrett, Lei Nie
Journal of Immunology. 2011-05-01 - 4 citationsA Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).Kaushal Parikh, Sumithra J. Mandrekar, Katie Allen-Ziegler, Brandt L. Esplin, Angelina D. Tan
The Oncologist. 2020-06-01 - 78 citationsThe use of pembrolizumab for the treatment of metastatic uveal melanoma.Lisa A. Kottschade, Robert R. McWilliams, Svetomir N. Markovic, Matthew S. Block, Jose Villasboas Bisneto
Melanoma Research. 2016-06-01
Grant Support
- Chronic Toll-Like Receptor Ligation And Hematopoietic Stem Cell AgingNational Institute On Aging2008–2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
